Vaccitech to Present at the H.C. Wainwright Global Investment Conference
May 20, 2022 11:30 ET
|
Vaccitech plc
OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 11, 2022 16:15 ET
|
Vaccitech plc
OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of...
Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®
April 06, 2022 16:15 ET
|
Vaccitech plc
OXFORD, United Kingdom, April 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments
March 25, 2022 07:15 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of...
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
March 07, 2022 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
January 18, 2022 03:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient...
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
January 13, 2022 16:34 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
December 13, 2021 16:05 ET
|
Vaccitech (UK) Limited
Complementary technology platforms, expertise and capabilities provide unique synergistic opportunities.Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvaxTM...
Vaccitech, 만성 HBV에 대한 임상1b/2a상 시험에서 긍정적인 초기 효능성 분석 결과 도출
December 07, 2021 10:30 ET
|
Vaccitech (UK) Limited
만성B형간염(CHB) 환자를 대상으로 한 3개월 간의 HBV002 임상연구 마친 27명의 환자들의 초기 데이터를 보면, 표면 항원(HBsAg) 수치가 눈에 띄는 변화를 나타냈으며, 이는 다른 종류의 부스트(VTP-300)와 저용량 nivolumab을 투여 받은 그룹에서 두드러져 HBV002 임상연구는 현재 4개 환자 그룹 모집 중으로...
Vaccitech在慢性HBV的1b/2a期临床研究中报告了极具前景的中期疗效分析
December 07, 2021 10:30 ET
|
Vaccitech (UK) Limited
在慢性乙型肝炎（CHB）患者中，27名完成了3个月HBV002研究患者的中期数据表明，表面抗原（HBsAg）水平出现了显著变化，特别是在接受具有异源加强型（VTP-300）低剂量纳武单抗的人群中。 HBV002研究招募了4个组来探索初免-加强载体组合，其中包括MVA-HBV（初免）+ MVA-HBV（加强）、ChAdOx1-HBV（初免）+...